Overview & Epidemiology

1. What is Charcot Neuroarthropathy?

Charcot neuroarthropathy (CN) — also called Charcot foot, Charcot arthropathy, and (in the older literature) Charcot joint or neuropathic osteoarthropathy — is a progressive, non-infectious, destructive arthropathy of bones, joints, and soft tissues of the foot and ankle (and, less often, other weight-bearing joints) that occurs in patients with peripheral sensory neuropathy.

The international (IWGDF / ADA / AOFAS / Rogers consensus, Diabetes Care 2011) working definition has three pillars:

• A neuropathic substrate — loss of protective sensation, almost always with autonomic neuropathy in addition.
• A precipitating event — often unrecognised: a minor sprain, an unappreciated fracture, surgery, or revascularisation.
• An inflammatory cascade — that proceeds, in the absence of nociceptive feedback, to bone resorption, fragmentation, dislocation, and ultimately deformity.

The pathognomonic clinical picture of acute CN is the unilateral, warm, swollen, erythematous foot in a neuropathic patient who is comfortable enough to walk on it. The skin temperature differential between the affected and contralateral foot is typically ≥2°C (often 4–8°C), which is the single most useful bedside sign and the one used for monitoring response to offloading.

2. Jean-Martin Charcot, 1868 — A Brief History

Jean-Martin Charcot (1825–1893) — the “founder of modern neurology” at the Salpêtrière in Paris — described the eponymous arthropathy in a series of patients with tabes dorsalis (tertiary neurosyphilis). His landmark paper, Sur quelques arthropathies qui paraissent dépendre d’une lésion du cerveau ou de la moëlle épinière (Arch Physiol Norm Pathol 1868), reported gross joint destruction in patients with posterior-column degeneration, and famously argued that the joint pathology was a direct consequence of the neural lesion — the neurotrophic theory of Charcot foot that survives, in modified form, today.

• 1703 — William Musgrave (De Arthritide Symptomatica) describes joint destruction following venereal disease — the earliest recognisable description.
• 1831 — John K. Mitchell (Philadelphia) reports joint disease following spinal cord injury.
• 1868 — Charcot publishes his Salpêtrière series of tabetic arthropathies.
• 1883 — Charcot & Féré describe a tarsal variant: the “pied tabétique”.
• 1936 — William Riely Jordan (Mayo Clinic, Arch Intern Med) describes the first definitive case in diabetes mellitus — a case associated with diabetic neuropathy rather than syphilis.
• 1947 — Bailey and Root broaden the diabetic case series.
• 1966 — Sidney Eichenholtz publishes Charcot Joints with the radiographic three-stage classification (development, coalescence, reconstruction) that remains the clinical workhorse.
• 1990 — James Brodsky introduces an anatomic classification (Type 1 midfoot, 2 hindfoot, 3A ankle, 3B calcaneus, 4 multiple, 5 forefoot).
• 1991 — Sella and Barrette add “Stage 0” — the pre-radiographic, MRI-only phase.
• 2008–11 — Jeffcoate, Game and colleagues articulate the unified inflammatory / RANK-L hypothesis.
• 2011 — The international consensus (Rogers, Frykberg, Armstrong et al., Diabetes Care) standardises terminology and management.

The shift in the dominant aetiology — from tabes dorsalis in 1868 to diabetic neuropathy in 2026 — maps the epidemiologic transition of the past century: as syphilis became treatable and diabetes became epidemic, the patient at the bedside changed completely while the joint pathology stayed the same.

3. The Aetiologic Spectrum

Any disease that produces dense peripheral sensory neuropathy in a weight-bearing limb can produce CN. The proportions have shifted dramatically over a century:

The classical teaching that “the joint involved hints at the cause” still holds: a Charcot knee in a middle-aged adult is syphilis until proven otherwise; a Charcot shoulder or elbow in a young adult points strongly to syringomyelia (and warrants a cervical-cord MRI before any orthopaedic intervention); a Charcot foot in a person with diabetes is diabetes until proven otherwise.

4. Epidemiology in Diabetes

Reported prevalence of CN in diabetics varies enormously — from 0.1% to 7% — depending on whether the denominator is all diabetics or only those with neuropathy, and whether the numerator includes Stage 0 disease (often invisible on plain films and therefore missed in chart-review studies). The largest US administrative-claims study (Lavery et al., Diabetes Care 2010) reported an annual incidence ~0.3% in diabetics with neuropathy, rising to ~13% lifetime prevalence in long-duration insulin-treated patients.

Demographic features:

• Diabetes type — T1 and T2 are both at risk; T1 patients tend to present younger (40s) and T2 patients in their 50s–60s. The absolute number is dominated by T2 because T2 is so much more prevalent.
• Glycaemic exposure — long duration (typically >10 years) and poor historical control (HbA1c >9%) confer most of the risk; current HbA1c at diagnosis is sometimes paradoxically near-normal because severe symptomatic neuropathy already implies cumulative damage.
• Obesity / weight — mechanically loads a foot already destabilised by neuropathy.
• Renal disease — ESRD on haemodialysis or post-transplant; transplantation itself (kidney or pancreas) is a recognised precipitant, possibly via osteopenia from immunosuppression and post-transplant hyperaemia.
• Sex — most series show a slight male predominance (~55%) but it is not striking.

The diabetic-foot epidemic is itself a function of global diabetes prevalence: ~537 million adults with diabetes worldwide in 2021 (IDF Atlas), projected to ~783 million by 2045. Even at the conservative 0.3%/year incidence, an aging, long-duration diabetic population will produce hundreds of thousands of new CN cases annually.

5. Anatomic Distribution — Where the Foot Breaks

The Brodsky anatomic classification (1990) maps the foot regions affected, in descending order of frequency:

The midfoot pattern — predominantly the tarsometatarsal (Lisfranc) and naviculocuneiform joints — is the single commonest, accounting for the rocker-bottom foot with plantar prominence at the midfoot, the most ulcerogenic of all CN deformities. The biology is pieced together in Part II and the staging in Part V.

Why the midfoot? Two converging arguments: (i) the tarsometatarsal joints are relatively unprotected by the gastrocnemius–Achilles complex, whose shortening in long-standing diabetes (the “equinus contracture”) drives gait pressure forward into the midfoot; (ii) the dense plantar ligamentous arches are particularly vulnerable to the local hyperaemic osteolysis described in Part II.

6. Clinical Presentation

CN typically presents in two clinical phases:

The classical neuropathic features are essentially universal at presentation: loss of vibration and 5.07 monofilament sensation, depressed Achilles reflex, dry skin from sympathetic denervation, and distended dorsal foot veins from abolished sympathetic vasoconstrictor tone (the substrate of the neurovascular theory in Part II). Deep tendon reflexes at the knee are often preserved.

The elevation test is a useful bedside manoeuvre: in acute CN, dependent erythema fades within 5–10 minutes of limb elevation as venous engorgement drains. In cellulitis, erythema persists regardless of position. This simple distinction reliably separates the two at the bedside in many cases — though it does not replace imaging.

7. The Differential Diagnosis

The differential of a hot, swollen, neuropathic foot is short but potentially catastrophic:

The clinical decision that matters most is Charcot vs. osteomyelitis, especially when an ulcer is present. The wrong diagnosis at this fork is consequential: treating Charcot as osteomyelitis exposes the patient to prolonged unnecessary IV antibiotics and, sometimes, amputation; treating osteomyelitis as Charcot misses a limb-threatening infection. MRI, covered in Part IV, is the modern arbiter, with the spatial pattern of bone marrow oedema being the single most useful sign.

A simple temperature-based MathJax-style relation captures the bedside threshold used widely: \(\Delta T = T_{\text{affected}} - T_{\text{contralateral}} \ge 2\,^\circ\text{C}\). When the foot has “cooled off” (\(\Delta T < 2\,^\circ\text{C}\) for >1 week), the acute phase is presumed to have transitioned to coalescence / consolidation, and progressive weight-bearing is gradually permitted.

8. Burden & Outcomes

CN is a sentinel of the broader diabetic-foot crisis:

• Foot ulceration — lifetime risk in diabetics ~25%; in CN-affected feet that share neuropathy and plantar prominence, ulcer rates exceed 35–50% (Game et al., Diabetes Care 2012).
• Major amputation — ~5–15% of patients with CN ultimately undergo major lower-extremity amputation, especially after recurrent ulceration with secondary osteomyelitis.
• Mortality — the 5-year mortality after diabetic-foot major amputation is ∼50–70%, exceeding that of breast, prostate and colorectal cancer combined (Armstrong, Boulton & Bus, NEJM 2017; Diabetic Foot Ulcers and Their Recurrence).
• Cost — in the US, mean annual healthcare expenditure for a patient with CN exceeds that of a non-CN diabetic by ~5×, driven by repeated casting, surgery, prosthetics, and care of secondary ulcers.
• Disability & quality of life — SF-36 physical scores in chronic CN are comparable to those of advanced congestive heart failure.

9. Where This Course Goes

The remainder of the course descends into the molecular, imaging, staging, conservative and surgical detail behind the picture sketched here: